Tim Walbert, Horizon Therapeutics CEO (via YouTube)
December 11, 2022 02:29 PM ESTUpdated 03:01 PM
Deals
Pharma

Up­dat­ed: Am­gen in ad­vanced talks for Hori­zon, WSJ re­ports; Sanofi pulls out

Drew Armstrong

Executive Editor

Drug­mak­ers Hori­zon and Am­gen are in ad­vanced talks about a deal, the Wall Street Jour­nal re­port­ed Sun­day, while Sanofi sep­a­rate­ly an­nounced Sun­day that it has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times